Intelligent Bio Solutions Inc. reported a robust fiscal third quarter for 2025, showcasing significant growth in both revenue and profit. The company achieved total revenues of $0.73 million, reflecting a 20% increase from the previous quarter. Gross profits experienced a remarkable 91% growth year-over-year, amounting to $341,368. This performance is attributed to the increased adoption of higher-margin cartridge sales, which now constitute 58% of the company's total revenue for the fiscal year ending March 31, 2025. During the quarter, Intelligent Bio Solutions added 35 new accounts, bringing the total number of active accounts to over 450. The company continued its international growth strategy, expanding access in key European markets and enhancing its product offerings with multilingual capabilities, including Arabic and Latin American Spanish. These developments are part of the company's broader strategy to scale globally and prepare for future market entries, including plans for the U.S. market. Total cash and cash equivalents as of March 31, 2025, stood at $2.81 million, with shareholders' equity at $4.94 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.